PRSS22 and metastatic malignant neoplasm in the lymph nodes: In subgroups with and without peripheral nerve invasion, age > 65 years, pathological grades II&III&IV, no lymph node metastasis, and T3&T4 staging, increased PRSS22 expression was associated with poor overall survival (Figure 6I).